INTRODUCTION
============

The secretion of extracellular vesicles (EVs) is a well-conserved evolutionary process that occurs from prokaryotic cells to all eukaryotes [@B001]. EVs are categorized by various nomenclatures based on their size, intracellular origin, and mode of formation (i.e., exosomes, ectosomes, and apoptotic bodies). Ectosomes are shedding microvesicles directly derived from the plasma membrane, whereas dying cells produce apoptotic bodies to prevent leakage of their toxic cellular components [@B002]. Initially, it was thought that all EVs originate directly from the plasma membrane by budding; however, exosomes are distinct from other EVs with respect to their origin, size, function, and composition. The term "exosomes" was first proposed in the late 1980s to describe small (30- to 100-nm) vesicles of endosomal origin that are released during reticulocyte maturation and are rich in 5'-nucleotidase activity [@B003]. Invagination of the endosomal membrane induces the formation of small vesicles, which in turn leads to the formation of multivesicular bodies (MVBs) and subsequent release of these vesicles through fusion with the plasma membrane. Subsequent studies have revealed that exosome secretion into extracellular media such as blood, saliva, and urine occurs in multiple cell types, including cancer cells [@B004].

In recent years, these nanoscale vesicles have garnered a lot of attention from cancer researchers because they contain bioactive molecules such as lipids, proteins, and nucleic acids that can be transferred from primary tumors to various organs and tissues [@B001],[@B005],[@B006]. Mounting evidence supports the role of exosomes in multiple aspects of cancer processes, such as transforming neighboring cells within the tumor microenvironment and enhancing the invasiveness and drug-resistant potential of other tumor cells through the transport of oncogenic elements [@B005]-[@B007]. Therefore, exosomes can create an ideal milieu in which primary tumor cells can interact with neighboring cells for successful growth and metastasis. In this review, we will focus on issues regarding 1) the way cancer cells organize and sort exosomes differently from normal cells; 2) the role of oncogenic elements of CCEs in invasion, metastasis, and drug resistance; and 3) how our current knowledge about CCEs can contribute to the development of novel biomarkers and therapeutic interventions.

MECHANISMS OF BIOGENESIS, SECRETION, AND UPTAKE OF EXOSOMES
===========================================================

Exosomes are formed as intraluminal vesicles (ILVs) through the endocytic pathway and budding into early endosomes and multivesicular bodies (MVBs). MVBs are defined by the presence of small, cytosol-containing ILVs that are formed from the limiting membrane of late endosomes [@B008]. The fate of MVBs is either fusion with lysosomes for cargo degradation or fusion with the plasma membrane for releasing ILVs to the extracellular milieu as exosomes [@B009] ([Fig. 1](#F001){ref-type="fig"}).

![Biogenesis, secretion, and intercellular communication of exosomes. Exosomes are formed as intraluminal vesicles (ILVs). Early endosomes are integrated into multivesicular bodies (MVBs), which are the source of exosomes through endosomal sorting complexes required for transport (ESCRT) machinery, lipids (such as ceramide), and the tetraspanins. During the process of ILV formation, proteins (membrane receptors, cytoplasmic proteins, tetraspanins), lipids (cholesterol, ceramide), and nucleic acids (DNA, mRNA, miRNA) are being incorporated into exosomes. MVBs fuse with lysosomes or with the cellular membrane to release exosomes into the extracellular space. Several Rab small GTPases (Rab 11, Rab 27, and Rab 35) are involved in transporting MVBs to the cell membrane and in exosome secretion. The uptake of exosomes into target cells is mediated by the fusion of exosomes with the cell membrane of target cells, by receptor-ligand interactions, or by endocytosis.](BMB-49-18-g001){#F001}

One of the well-known mechanisms that describe the formation of ILVs and cargo sorting involves the endosomal sorting complex required for transport (ESCRT) machinery [@B010]. ESCRT comprises four complexes (0, I, II, and III) plus associated proteins (i.e., VPS4, VTA1, ALIX, and TSG101). ESCRT 0 involves cargo clustering by recognizing and sequestering ubiquitinated transmembrane proteins in the endosomal membrane. ESCRT I and II induce membrane deformation into buds with sorted cargo, and ESCRT-III drives vesicle scission [@B010].

However, it should be noted that not all proteins are required for ubiquitination for their sorting into MVBs, and that ESCRT-independent mechanisms have been found to support that MVBs and ILVs can form in the absence of ESCRT function as inactivation of key proteins in the four different ESCRT complexes cannot block MVB formation [@B011]. For example, tetraspanins can get into inwardly budding vesicles without ubiquitination owing to their intrinsic nature to partition into lipid raft-like subdomains of the plasma membrane [@B012]. These subdomains are characterized by the lateral interaction between certain proteins and lipids and provide an important signaling function by placing signaling receptors in close proximity to promote their physical and functional interactions [@B013]. In addition to these functions, lipid raft-like subdomains can generate membrane budding and fission by a ceramide-triggered process, suggesting an ESCRT-independent mechanism of MVB formation. It is not currently known whether mechanisms involving ESCRT, lipids, or tetraspanins act on the same MVB or on different MVBs ([Fig. 1](#F001){ref-type="fig"}).

The subsets of ILVs within MVBs target cargo for lysosomal degradation in an ESCRT-dependent and lipid (ceramide)-independent manner. On the other hand, other subsets of ILVs release cargo to the cell's exterior in the form of exosomes, which appear to be ceramide biosynthesis-dependent and ESCRT-independent ([Fig. 1](#F001){ref-type="fig"}). The latter process of directed transport involves multiple Rab family GTPases (Rab 11, Rab 27, and Rab 35) and SNARE family members (VAMP7 and YKT6) for targeted fusion with the plasma membrane [@B014]. It remains to be investigated how cancer cells, as opposed to normal cells, package exosomes and regulate the sorting (degradation in the lysosome vs. release of exosomes) of vesicles within MVBs. Special sorting mechanisms that target tumor-suppressing elements containing ILVs to the lysosome, as well as direct oncogenic-elements containing ILVs to the plasma membrane, are probably present in invasive cancer cells. The tumor microenvironment may play a role in exosome secretion, since Rab GTPases 27a and 27b promote exosome secretion in response to hypoxia, which is frequently encountered in tumors [@B015].

Adhesion of exosomes to target cells depends upon transmembrane proteins expressed in exosomes and target cells. In cancer cells, the binding and uptake of exosomes to target cells involve a tetraspanin-integrin complex [@B016], [@B017]. Recent evidence indicates that the integrin expression pattern in exosomes directs the sites of metastasis. For example, exosomal integrins α6β4 and α6β1 are associated with lung metastasis, whereas exosomal integrin αvβ3 integrin is associated with liver metastasis [@B017]. This study suggests that specific composition of exosomes contribute to organotropism associated with metastatic cancers. Uptake and internalization of exosomes to target cells can alter target cell functions by directly releasing their cargo into cytoplasm or by initiating juxtracrine signaling by means of receptor-ligand interactions [@B018], [@B019] ([Fig. 1](#F001){ref-type="fig"}).

ONCOGENIC ELEMENTS FOUND IN CCEs
================================

Cancer cells have been shown to produce excessive amounts of exosomes (referred to as cancer cell-derived exosomes (CCEs) via biological fluids. CCEs contain oncogenic elements including a variety of proteins, lipids, mRNAs, and microRNAs that can initiate the signaling pathways in tumor- and metastasis-promoting processes [@B020]. The new techniques such as stable exosome purification, RNA sequencing, proteomics, and lipodomics have allowed cancer researchers to understand the mechanisms by which CCEs manipulate the local and distant environment to facilitate cancer growth and dissemination.

Protein content
---------------

Electron microscopic and proteomic analyses of exosomes reveal that the protein content of exosomes is derived mainly from endosomes, cytoplasm, and plasma membrane but not from other intracellular organelles, which suggests that exosomes represent endosomal compartments [@B021]. Owing to their biogenesis through the endosomal network, exosomes contain specific proteins that are involved in intracellular membrane fusion and transport (Rab GTPases, annexins, and flotillin), tetraspanins (CD9, CD63, CD81, and CD82), heat shock proteins (Hsp60, Hsp70, and Hsp90), and proteins involved in MVB biogenesis (TSG101, Alix) [@B004], [@B017], [@B021]. They represent an evolutionarily conserved set of proteins that are commonly expressed in most exosomes, and such expression has been used to confirm the presence of exosomes in body fluids.

On the other hand, another group of unique exosomal proteins is specifically expressed in certain types of cells. These unique proteins are frequently found in CCEs depending on the cancer type and stage. Cancer-associated exosomal proteins play essential roles in the progression of these cancers by transferring their oncogenic, immunosuppressive, and metastatic functions to the primary tumor microenvironment or to metastatic niches. For example, glioma cells deliver the oncogenic mutant epidermal growth factor (EGF) receptor variant III (EGFRvIII) via exosomes to cells lacking EGFRvIII expression [@B022]. The presence of EGFRvIII confers on these cells the ability to become anti-apoptotic and to grow in an anchorage-independent manner [@B022]. Anti-apoptotic and angiogenic mediators, such as vascular endothelial growth factor (VEGF), can be transferred to target cells to enhance the ability of recipient cells to morphologically transform [@B022]. Mutant KRAS-expressing colon cancer cells transfer this constitutively active mutant oncogene into cells expressing wild-type KRAS via CCEs and increase the growth and tumorigenicity of recipient cells [@B023]. CCEs can also confer drug resistance on recipient cells; for example, through the intercellular transfer of drug transporter MDR-1 via CCEs, docetaxel-resistant prostate cancer cells can induce chemoresistance in non-resistant prostate cancer cells [@B024]. These findings nicely support the role of CCEs in increasing the tumorigenic potential and chemoresistance of recipient cells by malignant cancer cells.

CCEs secreted from the primary tumor play a role in establishing pre-metastatic niches that recruit metastasizing tumor cells and provide the environment for their subsequent growth. Highly metastatic melanoma-driven exosomes are able to convert bone marrow progenitors to a pro-metastatic phenotype through the hepatocyte growth factor (HGF) receptor, MET oncoprotein [@B025]. CCEs from melanoma cells induce vascular leakiness at pre-metastatic sites and prepare sentinel lymph nodes for melanoma recruitment, extracellular matrix deposition, and vascular proliferation [@B026]. CCEs are involved in tumorstromal interaction by transferring extracellular matrix metalloproteinase inducer (EMMPRIN) (also known as basigin and CD147) from tumor cells to fibroblasts [@B027]. EMMPRIN stimulates the expression of metalloproteinase (MMP-1) in fibroblasts and the remodeling of the extracellular matrix [@B027]. Exosomes secreted from fibroblasts could also stimulate breast cancer cell motility and invasion by stromal mobilization of the Wnt-PCP signaling pathway [@B028].

Evading immune response is one of the important hallmarks of cancer progression. There is considerable evidence to suggest that CCEs suppress tumor-specific immune responses in the host [@B029], [@B030]. This somewhat contradicts previous reports that MHC class I molecules are present on the surface of exosomes secreted from virtually all cell types and can induce CD8-positive T-cell activation [@B009], [@B031]. In addition, CCEs can be the source for tumor antigens that lead to activation of antigen-presenting cells and cytotoxic T lymphocytes [@B032], [@B033]. However, cancer cells evolved the CCE-dependent strategies to avoid being recognized by the immune system. For example, Fas-L-, TRAIL-, or galectin-9-bearing CCEs can induce apoptosis of T lymphocytes [@B029], [@B030], [@B034]. The presence of prostaglandin E2 (PGE2) and transforming growth factor beta (TGF-β) in CCEs induces the accumulation of myeloid-derived suppressor cells (MDSCs) by switching the differentiation pathway of bone marrow myeloid cells to MDSCs [@B035]. Accumulation of MDSCs leads to regulatory T-cell (Treg) expansion and apoptosis of tumor-reactive CD8-positive T lymphocytes [@B036]. The results of these studies support the view that CCEs trigger immunosuppressive responses, which in turn favors the metastatic environment.

Nucleic acid content
--------------------

Analysis of mRNA and miRNA profiles in CCEs and in parental cancer cells shows different patterns, suggesting a specific mechanism in the sorting of these nucleic acids into exosomes [@B037]. It remains to be seen whether cancer cells develop the packing mechanisms that select oncogenic mRNAs and miRNAs (oncomiRs) over tumor-suppressive miRNAs into CCEs. In addition to packing of selective nucleic acids to CCEs, recent studies have demonstrated that CCEs in breast cancer cells contain the RISC-loading complex (Dicer, AGO2, and TRBP) that could process premature miRNAs into mature oncomiRs [@B038]. These oncomiRs were shown to induce a neoplastic phenotype of targeted normal cells [@B038].

Studies of miRNA profiling have identified a group of exosomal miRNAs that are present at higher levels in CCEs than in normal exosomes. For example, four miRNAs (miR-1246, miR-4644, miR-3976, and miR-4306) are more abundant in CCEs from the serum of patients with pancreatic cancer than in exosomes found in the serum from healthy donors [@B039]. The levels of miR-200c and miR-214 are elevated in CCEs derived from patients with ovarian cancer and correlate with ovarian cancer stage [@B040]. Another study showed that seven miRNAs (let-7a, miR-1229, miR-1246, miR-150, miR-21, miR-223, and miR-23a) were significantly elevated in CCEs secreted from patients with primary colon cancer only at the early stage and were then decreased after surgical resection of the primary tumors, suggesting that the level of these miRNAs could be a useful tool for the early detection of colon cancer [@B041].

The transfer by CCEs of oncomiRs from the primary tumor or macrophages into recipient cells is associated with enhanced metastatic potential. Interleukin-4 (IL-4)-activated tumor-associated macrophages (TAMs) release exosomes that contain miR-223, a miRNA specific for IL-4-activated macrophages [@B042]. Exosome-mediated delivery of miR-223 into co-cultured breast cancer cells enhanced their ability to invade [@B042]. Gastric cancer tissue-derived mesenchymal stem cells (GC-MSCs) transfer exosomal miRNAs (miR-221/222) to gastric cancer cells, thus increasing gastric cancer cell migration [@B043]. CCE-mediated secretion of miR-21 and miR-29a allows them to bind directly to toll-like receptors (TLRs) in immune cells, which triggers a TLR-mediated pro-metastatic response that leads to tumor growth and metastasis [@B044]. In leukemia cells, an exosomal miR17-92 cluster consisting of six miRNAs (miR-17, -18a, -19a, -20a, -19b, and -92a) plays a role as communicator between cancer and endothelial cells to promote tumor angiogenesis [@B045]. Exosomal miR105 secreted from metastatic breast cancer cells contributes to cancer metastasis by destroying the endothelial barriers through down-regulation of the tight junction protein ZO-1 [@B046]. All this evidence suggests the efficacy of oncomiRs in CCEs in developing personalized diagnostics and therapeutics.

Lipidomic content
-----------------

Exosomes have distinct lipid compositions in comparison to whole cell membranes. They are abundant in cholesterol, sphingomyelin, glycerophospholipids, phosphatidylserine, phosphatidylinositol, and ceramide [@B047]. As for the connection between lipid dynamics and exosome biosynthesis, it has been reported that various lipids or lipid-related enzymes interact with proteins of the ESCRT machinery. For example, phosphatidylserine is required for the heat shock protein hsc-70-dependent microautophagy process generating exosomes [@B048]. Lysobisphosphatidic acid association with the ESCRT III-associated protein Alix alters the dynamics of MVB and late endosome membrane [@B049], [@B050]. Alix also binds to bismonoacylgly-cerolphosphate that is formed by phospholipase D2, an essential enzyme for exosome production [@B051]. Independent of ESCRT protein machinery, the neutral lipid ceramide plays a key role in exosome biosynthesis by involving miRNA packaging [@B052]. Cholesterol contributes to the secretion of flotilin-2-positive exosomes [@B053]. In mesenchymal stem cells, sphingolipid cholesterol-rich microdomains (lipid rafts) are linked to the biogenesis and secretion of exosomes [@B054], [@B055].

How the lipid composition of CCEs differs from that of normal exosomes is not well understood. Combined approaches using shotgun lipidomics analyses of metastatic prostate cancer cells (PC3) and their exosomes revealed an overall 8.4-fold enrichment of lipids per mg of protein in CCEs [@B056]. In this study, significant amounts of phosphatidylserine, cholesterol, sphingomyelin, and glycosphingolipids were found in exosomes, as compared with parental PC3 prostate cancer cells [@B056]. These lipids could potentially be used as biomarkers of prostate cancer. In another study, shotgun lipidomic analysis of colorectal cancer cell line (LIM1215)-derived exosomes identified over 520 individual lipids [@B057]. In a comparison with cellular lipid profiles, researchers observed the relative enrichment of exosomes with certain lipid classes, including sphingolipids, sterol lipids, glycerolipids, and glycerophospholipids [@B057]. Most likely, the strategy of analysis used in this study can provide the basis for wide and comprehensive lipidome profiling of CCEs derived from other types of cancer cells and tissues.

Exosomal lipids can influence target cells by carrying lipid-related enzymes and bioactive lipids that influence signaling, inflammation, immunity, and their own biogenesis. More evidence suggests that lipids in CCEs can induce tumor growth and drug resistance. PGE2 is carried by CCEs and trigger host immunosuppression to allow tumor development [@B058]. CCEs secreted from murine mammary adenocarcinoma cells contain PGE2 that is related to the induction of MDSC that down-regulate the functions of T cells [@B035]. Function-blocking antibody against PGE2 blocks CCE-dependent MDSC induction and tumor growth [@B035]. Exosomes from macrophages have been shown to contain enzymes for the biosynthesis of leukotrienes (LTs) that are potent pro-inflammatory lipid mediators [@B059]. Receptors for LTB4 and LTC4 are overexpressed in some cancers, suggesting that exosomal LTs are probably involved in tumor development. Exosome biogenesis and secretion from B-cell lymphoma involve the phosphatidylcholine transporter ABCA3 [@B060]. ABCA3 is implicated in shielding target cells from treatment with rituximab, an antibody that targets the B-cell lymphocyte antigen CD20 [@B060]. Although ABCA3 is overexpressed in B-cell lymphomas, pharmacological inhibition or siRNA-mediated silencing of ABCA3 expression restores the susceptibility of target cells to antibody-mediated cell lysis, suggesting that ABCA3-dependent exosome release is implicated in resistance to immunotherapy [@B060].

CLINICAL APPLICATIONS INVOLVING CCEs
====================================

Exosomes for cancer diagnosis and prognosis
-------------------------------------------

Circulating serum exosomes merit consideration as biomarkers for the early detection of cancer burden, because exosomes are stable at 4℃ for 4 days and at −70℃ for long-term storage [@B040]. The proteomics profiling of CCEs showed that cell-surface proteins in CCEs could be used as biomarkers for the diagnosis and prognosis of cancer. For example, Skog et al. demonstrated that the EGFRvIII mutant is expressed in a subtype of glioblastoma, and its expression is detected in serum circulating exosomes [@B061]. This finding helped patients with glioblastoma to avoid invasive brain tumor biopsy, since determining EGFR status from blood samples will provide the information regarding the nature of this disease. In the colorectal cancer model, one study indicates that the level of circulating exosomes itself is related to poor prognosis and shorter survival of patients [@B062]. Studies from immortalized hepatocellular carcinoma (HCC) revealed that CCEs could represent the cancer stage, since metastasis-inducing factors such as c-Met, caveolins, and S100 family members are present only in highly metastatic HCC-derived exosomes [@B063]. Exosomes isolated from the blood of patients with breast cancer who had the worst prognosis showed metastatic and stemness-like signatures in the nucleic acids, suggesting that exosome-derived nucleic acids (mRNAs and miRNAs) can be used as suitable prognostic markers [@B064]. Because the isolation of exosomes from patient samples is non-invasive and relatively easy, CCEs could emerge as the main source for diagnostic and prognostic markers of cancer, as long as cancer-specific markers in CCEs are successfully screened and identified.

Therapeutic applications of exosomes
------------------------------------

Because exosomes represent a system that delivers selected cargo to target cells, they have great therapeutic potential [@B065]. Therapeutic designs that block pathological intercellular transfer mediated by exosomes can prevent CCE-mediated tumor formation and metastasis. In this regard, the impairment of exosome secretion from cancer cells could be a potential target for cancer therapy. An increase in intracellular calcium levels stimulates exosome secretion [@B066]. Blocking the function of H^+^/NA^+^ and Na^+^/Ca^+^ channels by means of dimethyl amirolide (DMA), an inhibitor of these two channels, effectively reduces exosome release in CT26-bearing mice, since these two channels regulate intracellular calcium levels [@B067]. DMA also blocks the immunosuppressive function of bone marrow myeloid cells by inhibiting STAT3 phosphorylation [@B067]. Another preclinical study involving the sphingomyelinase 2 inhibitor GW4869 showed that exosome-mediated tumor growth and metastasis are inhibited by this drug compound in lung cancer-bearing mice [@B044].

Alternatively, exosomes themselves can be used as delivery vesicles for therapeutic agents such as small interfering RNAs (siRNAs) or drug molecules that inhibit the functions of targeted cancer cells. Exosomes as a delivery tool merit consideration because they are not only bioavailable but also resistant to metabolic processes. Multiple studies support this possibility. Intravenous injection of exosomes carrying let-7a miRNA significantly reduced tumor formation in mice with EGFR-expressing breast cancer cells [@B068]. Although the bioavailability and uptake of polyphenol compounds such as curcumin have been the major issue, curcumin becomes more stable and concentrated in blood once it is incorporated into exosomes [@B069]. Clinical trials involving dendritic cell-derived exosomes for immunotherapy have been carried out [@B070], [@B071]. Exosomes can be used for targeted drug delivery because they can lower immunogenicity and toxicity if they can selectively target cancer cells but not normal cells. For example, the fusion of integrin αv-specific peptide to exosomal membrane protein led to highly efficient targeting of chemotherapeutics such as doxorubicin to integrin αv-positive breast cancer cells and the inhibition of tumor growth in vivo without overt toxicity [@B072]. Therefore, using exosomes as a drug carrier is likely to create a new opportunity for cancer treatment without side effects originating from off-target effects.

CONCLUSIONS AND FUTURE DIRECTIONS
=================================

Exosomes have emerged as a novel class of intercellular signal mediators that are involved in various pathological conditions, including cancer. In this review, we discussed the recent progress in studies related to CCEs in terms of their oncogenic elements and therapeutic potentials. Compelling evidence from the recent literature supports the idea that CCEs can facilitate cancer invasion and metastasis by creating a fertile environment for tumor growth in the vicinity of neoplastic lesions as well as for distal metastases. The mechanisms by which CCEs achieve these effects include enhancement of the pro-tumorigenic potential of the recipient cells by introducing oncogenic elements and suppressing host immune responses. Exosomes also offer many novel therapeutic possibilities owing to their properties associated with easier detection and delivery potential. Advances in technology of exosome isolation, characterization, and in vitro modification allow selective delivery of the chosen exosome cargos to target cells. Detection of exosomes in bodily fluids represents a promising option for acquiring pathologic information for the diagnosis and prognosisof cancer. Future studies should focus on unresolved issues, such as determining the intricacies of CCE-specific biogenesis and sorting, enhancing the purity of exosome isolation, anddeveloping safer routes of administration to achieve maximal targeted delivery of therapeutic exosomes.
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